Found a new study in the Archives of Internal Medicine, that is not the removal of the ovaries during a hysterectomy bad for the heart, as opposed to what is found in other studies.The author of an accompanying editorial explains the conflicting data from these two large studies stressed the importance of talking to your doctor about a family history of heart disease or ovarian cancer.
About 600,000 women each year undergo hysterectomy to relieve abnormal uterine bleeding, to remove the fibroids or for other health reasons? After Caesarean section, hysterectomy is the second most common surgery performed in women of childbearing age in the United States. About half of all women who undergo the surgery have their ovaries removed, with higher rates among women who are older. But there are concerns that the change in hormones after surgery may increase the risk of osteoporosis, heart disease and stroke. To combat this, use advise women advise women, hormone replacement therapy hormone levels hormone levels, but is based with the recent reports on the health risks of HRT, based on data from the same Women ‘s Health Initiative, this practice has fallen into disfavor.In addition, Tyagi and workers, the effect of silibinin for drugs currently clinical trials lung cancer comparison. Dignity of drugs other signaling pathways – similar to cut at to manufacturing of COX2 and iNOS – different linked chains? in combination and that the chains of the inhibition JAK1 / 2 and MEK in combination, and and the inhibition of signal pathways of EGFR and NF-kB in combinations blocks the ability of of STAT1 and STAT3 in order the energy which it needs to finally signalize catch COX2 and iNOS production.
Stop STAT1 and STAT3 and the chain of which leads COX2 and iNOS – and growth of of lung tumors with them. – ‘The relatively nontoxic material – one derivative of milk thistle, called silibinin – could of inhibiting the upstream signals to the expression on COX2 and iNOS,’says Alpna Tyagi, of the University of Colorado Skaggs School of Pharmacy at. Tyagi working in the lab the University of Colorado Cancer Center researchers AM Rajesh Agarwal.